CoChat

Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: A primer for clinicians

Bays, H. · 2008 · Drugs of Today
Cited by 39

The DOI matches its Crossref record.

Abstract

Very high triglyceride (TG) levels may cause pancreatitis. Elevated TG levels are also often, but not always, a risk factor for atherosclerotic coronary heart disease. Omega-3 fatty acids are polyunsaturated fatty acids found in the oil of fish and other seafood that, when consumed, lower TG levels and reduce the risk of cardiovascular events. Prescription omega-3-acid (P-OM3) ethyl ester is a fish oil formulation that has undergone the rigorous regulatory steps required to obtain US Food and Drug Administration approval as a prescription drug. P-OM3 is derived from marine fish, which are high in omega-3 fatty acids. While omega-3 fatty acids may sometimes increase low- density lipoprotein cholesterol (LDL-C) levels in hypertriglyceridemic patients, non-high-density lipoprotein cholesterol (non-HDL-C) levels are often decreased. This has clinical significance because: 1) non-HDL-C sums the cholesterol carried by atherogenic lipoproteins beyond that of LDL-C alone; 2) non-HDL-C is a better predictor of atherogenic risk compared to LDL-C alone; and 3) after LDL-C treatment goals have been reached, non-HDL-C is a recommended secondary lipid treatment target in patients with persistent TG > or = 200 mg/dl. This paper reviews the U.S. treatment indications for P-OM3, clinical evaluation of hypertriglyceridemic patients, importance of elevated TG levels, relevant TG biochemistry and metabolism, illustrative genetic dyslipidemias, lipid treatment recommendations, fat and fatty acid biochemistry, omega-3 fatty acid biochemistry, and the basis behind recommending omega-3 fatty acids to reduce cardiovascular risk. Finally, this review examines P-OM3's lipid and cardiovascular effects, safety, and tolerability, as well as its practical role in patient management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1358/dot.2008.44.3.1166387

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 39

Metadata

Authors
Bays, H.
Venue
Drugs of Today
Publisher
Portico
Published
2008
Volume
44
Issue
3
Pages
205
ISSN
  • 0025-7656 (ISSN-L)
  • 1699-4019
OpenAlex
W2001687790
Cited by
39
References
0
FWCI
6.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: A primer for clinicians. https://app.cochat.ai/papers/10.1358/dot.2008.44.3.1166387
The paper
Bays, H. (2008). Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: A primer for clinicians. Drugs of Today. https://doi.org/10.1358/dot.2008.44.3.1166387

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.